Because TP53 mutations did not affect the prognosis of IDH wild-type gliomas according to our study, we classified gliomas as IDH mutant gliomas without TP53 mutations, IDH mutant gliomas with TP53 mutations, and IDH wild-type gliomas. This evidence concerns the gene IDH2 and central nervous system cancer.